ARIDIS PHARMACT Shares Outstanding 2018-2021 | ARDS

ARIDIS PHARMACT shares outstanding from 2018 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ARIDIS PHARMACT Annual Shares Outstanding
(Millions of Shares)
2020 9
2019 8
2018 3
2017 0
ARIDIS PHARMACT Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 11
2021-03-31 10
2020-12-31 9
2020-09-30 9
2020-06-30 9
2020-03-31 9
2019-12-31 8
2019-09-30 9
2019-06-30 8
2019-03-31 8
2018-12-31 3
2018-09-30 4
2018-06-30 0
2018-03-31 0
2017-12-31
2017-09-30 0
2017-06-30 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.046B $0.001B
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29